original characterizations
I739 Peripheral vascular disease, unspecified Peripheral vascular disease, unspecified, I739 Peripheral vascular disease, unspecified

The results of tests on the treadmill include the Walk Impairment Questionnaire( WIQ), which measures the relationship between the posterior systolic blood pressure of the tibia and dorsal foot at rest( ankle) and the brachial blood pressure.
Efficacy as measured

At the end of Weeks 4, 8, and 12( minimum) and at the end of Week 10( maximum)

descriptive description of each of the various categories of outcomes

Different treatment group's adverse reactions. The detailed descriptions of the lab abnormalities that have been identified will also be provided.
Criteria for inclusion:

• Give authorization in writing.

•> 40 years of age.

• Whether they are postmenopausal( i .e., not menstruating after 12 months) or surgically sterile, both men and women are affected by this.

• A history of sporadic claudication lasting longer than six months( stage il de Fontaine).
• An ABI of> 0 in at least one artery in each leg, with an ABL of> 0 in at least one leg.

• A reduction of> 20 mmHg in the supine SBP in at least one leg measured in the first two minutes following the treadmill selection test's suspension in the posterior tibial artery or the back of the foot.

• A 5-minute treadmill-based initial selection test will also be conducted. The patient should be given the reason for the suspension if the patient stops performing the exercise after five minutes.

Patients who experience chest pain during the screening test will be exempt from participating in the future.
Criteria for exclusion:

https://www.echemi.com/products/pd180914118418-edonentan.html